# Renal HEIR Study: Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes Study

Study · id `cardio:ct-nct03584217` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03584217](<https://clinicaltrials.gov/study/NCT03584217>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03584217

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 100 participants.

## Technical summary

Registry record NCT03584217. Allocation not applicable; no masking; primary purpose diagnostic. Start 2018-10-01 (actual); primary completion 2023-06-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase: Phase 1/2
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT03584217, source copy `cardio:ctgov-nct03584217-2023-08-15`, retrieved 2026-10-26)
- Started: 2018-10-01 (actual) (ClinicalTrials.gov record NCT03584217, source copy `cardio:ctgov-nct03584217-2023-08-15`, retrieved 2026-10-26)
- Primary completion: 2023-06-30 (actual) (ClinicalTrials.gov record NCT03584217, source copy `cardio:ctgov-nct03584217-2023-08-15`, retrieved 2026-10-26)
- Completion: 2023-10-30 (anticipated) (ClinicalTrials.gov record NCT03584217, source copy `cardio:ctgov-nct03584217-2023-08-15`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03584217, source copy `cardio:ctgov-nct03584217-2023-08-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03584217-2023-08-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Renal HEIR Study: Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes Study
- Acronym: Renal-HEIR
- Condition: Type 2 Diabetes Mellitus
- Condition: Obesity
- Condition: Nephropathy
- Condition: Adolescent Obesity
- Intervention (Drug): Aminohippurate Sodium Inj 20%
- Intervention (Drug): Iohexol Inj 300 MG/ML
- Intervention (Procedure): Renal Biopsy
- Lead sponsor: University of Colorado, Denver
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: University of Colorado, Denver (`cardio:org-university-of-colorado-denver`)

## Provenance

Content hash: 6bff78b9da1fde672b06232640f5f4ff9c111a76a73ce8fdeccccb6293339a36
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
